Safety of Thiopurines and Anti-TNF-α Drugs During Pregnancy in Patients with Inflammatory Bowel Disease
Overview
Authors
Affiliations
Objectives: The safety of thiopurines and anti-tumor necrosis factor-α (TNF-α) drugs during pregnancy remains controversial, as the experience with these drugs in this situation is limited. Our aim is to assess the safety of thiopurines and anti-TNF-α drugs for the treatment of inflammatory bowel disease (IBD) during pregnancy.
Methods: Retrospective, multicenter study in IBD patients. Pregnancies were classified according to the therapeutic regimens during pregnancy or during the 3 months before the conception: non-exposed group, pregnancies exposed to thiopurines alone (group A), and pregnancies exposed to anti-TNF-α drugs (group B). An unfavorable Global Pregnancy Outcome (GPO) was considered if pregnancy developed with obstetric complications in the mother and in the newborn.
Results: A total of 187 pregnancies in the group A, 66 pregnancies in the group B, and 318 pregnancies in the non-exposed group were included. The rate of unfavorable GPO was different among the three groups (31.8% in non-exposed group, 21.9% in group A, and 34.8% in group B), being lower in pregnancies under thiopurines than among non-exposed (P = 0.01). The rate of pregnancy complications was similar among the three groups (27.7% in non-exposed, 20.9% in group A, and 30.3% in group B). The rate of neonatal complications was different among the three groups (23.3% in non-exposed group, 13.9% in group A, and 21.2% in group B), being lower in pregnancies under thiopurines than among non-exposed (P = 0.01). In the multivariate analysis, the treatment with thiopurines (odds ratio = 0.6; 95% confidence interval = 0.4-0.9, P = 0.02) was the only predictor of favorable GPO, whereas maternal age >35 years at conception was the only predictor of unfavorable GPO. The treatment with anti-TNF-α drugs was not associated with an unfavorable GPO.
Conclusion: The treatment with thiopurines and anti-TNF-α drugs does not seem to increase the risk of complications during pregnancy and does seem to be safe for the newborn.
Yen H, Wu J, Wang H, Chang T, Chang C, Chang C Intest Res. 2024; 22(3):213-249.
PMID: 39099217 PMC: 11309818. DOI: 10.5217/ir.2023.00050.
Huang W, Zhang X, Zhang L, Dai X, Chen H, Xie Q BMC Pregnancy Childbirth. 2024; 24(1):251.
PMID: 38589784 PMC: 11000337. DOI: 10.1186/s12884-024-06443-w.
Squirell E, Meade S, Leung Y J Can Assoc Gastroenterol. 2024; 7(1):121-131.
PMID: 38314178 PMC: 10836983. DOI: 10.1093/jcag/gwad056.
Saudi consensus guidance for the management of inflammatory bowel disease during pregnancy.
Azzam N, AlMutairdi A, Almudaiheem H, AlAmeel T, Bakkari S, Alharbi O Saudi J Gastroenterol. 2023; .
PMID: 38099556 PMC: 11379253. DOI: 10.4103/sjg.sjg_318_23.
IBD and Motherhood: A Journey through Conception, Pregnancy and Beyond.
Caballero-Mateos A, Quesada-Caballero M, Canadas-De la Fuente G, Caballero-Vazquez A, Contreras-Chova F J Clin Med. 2023; 12(19).
PMID: 37834837 PMC: 10573266. DOI: 10.3390/jcm12196192.